TAK-220

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2008
01220042008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
In addition to being an important receptor in leukocyte activation and mobilization, CCR5 is the essential coreceptor for human… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2007
2007
TAK-652, a novel small-molecule chemokine receptor antagonist, is a highly potent and selective inhibitor of CCR5-using (R5… (More)
Is this relevant?
Review
2007
Review
2007
HIV entry and fusion are two steps in the viral life cycle that can be targeted by several classes of antiviral drugs. The… (More)
Is this relevant?
2006
2006
We incorporated various polar groups into previously described piperidine-4-carboxamide CCR5 antagonists to improve their… (More)
Is this relevant?
2005
2005
G protein-coupled receptor CCR5 is the main coreceptor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1), and… (More)
Is this relevant?
2005
2005
TAK-220 is a member of a novel class of chemokine receptor antagonists and is highly specific to CCR5, as determined by receptor… (More)
Is this relevant?
2005
2005
TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2005
Review
2005
There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and > 30 anti-HIV compounds under (pre)clinical… (More)
Is this relevant?
2004
2004
In recent years, significant progress has been made towards the chemotherapy (and ?prophylaxis) of HIV infections. This progress… (More)
Is this relevant?
Review
2004
Review
2004
Considerable advances have been made in the last years in the design of derivatives acting as inhibitors of HIV entry and fusion… (More)
Is this relevant?